11/9/2018 | CVLM | Corsicanto forces exchange for $30 million of 3.5% notes due 2047
|
10/22/2018 | CVLM | Amarin unit forces conversion on $30 million of 3.5% notes due 2047
|
2/15/2017 | CVLM | Amarin unit calls $133,000 of remaining 3.5% exchangeables due 2032
|
1/20/2017 | CVLM | Amarin unit buys back nearly all 3.5% exchangeables due 2032, issues new notes due 2047
|
9/14/2016 | CVLM | Amarin, Corsicanto mandatorily exchange 3.5% exchangeables due 2032
|
8/26/2016 | CVLM | Amarin, Corsicanto to mandatorily exchange 3.5% notes due 2032
|
11/20/2015 | CVLM | Amarin buys back $16.2 million 3.5% exchangeables at discount, issues $31.3 million notes
|
11/4/2015 | PP | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Morning Commentary: Convertibles primary remains quiet; Tesla Motors adds after earnings miss
|
8/7/2015 | CV | Market Commentary: Fluidigm ‘comes in’ on the back of disappointing earnings; Iconix drops; Post expands slightly
|
7/10/2015 | PP | Amarin settles $58.65 million ADS placement with $5.83 million tranche
|
3/31/2015 | PP | Amarin wraps $52.82 million of $58.65 million private placement of ADS
|
3/16/2015 | PP | Market Commentary: Salix convertibles add on sweetened Valeant deal; Amarin extends gains; Actavis in action
|
3/16/2015 | CV | Market Commentary: Salix convertibles add on sweetened Valeant deal; Amarin extends gains; Actavis in action
|
3/6/2015 | PP | Amarin intends to conduct $52.82 million private placement of its ADS
|
10/16/2014 | PP | Amarin extends expiration date of October 2009 warrants to 2015
|
5/15/2014 | CV | Market Commentary: New Spirit Realty bonds around par; planned TAL Education in focus; NQ Mobile plunges
|
5/15/2014 | CVLM | Amarin to issue new notes in exchange for $118.73 million 3.5% notes
|
10/17/2013 | CV | Market Commentary: Amarin sinks on FDA panel rejection; Arris eyed on redemption notice; Aegean Marine on tap
|
12/6/2012 | PV | Amarin lines up $100 million hybrid debt financing with Pharmakon fund
|
10/5/2012 | CV | Market Commentary: Convertibles mostly quiet; WellPoint puts in notably strong week; Home Inns drops on swap
|
8/10/2012 | CV | Market Commentary: MGM better on outright demand; Janus adds on investment stake; Hornbeck trades up, in line
|
7/27/2012 | CV | Market Commentary: Amgen in line to slightly lower on earnings; Gilead, Coinstar in line as well; Amarin off
|
7/26/2012 | CV | Market Commentary: United Therapeutics gains on hedge after earnings; Cash America down outright, up on hedge
|
1/11/2012 | CV | Market Commentary: New PHH surges out of the chute; existing PHH convertibles improve; NuVasive up on hedge
|
1/4/2012 | CV | Market Commentary: New Amarin drops below par; TiVo jumps on AT&T settlement; Alliance Data flat to lower
|
1/4/2012 | CV | New Issue: Amarin unit prices $150 million 20-year exchangeables at 3.5%, up 25%
|
1/3/2012 | CV | Amarin unit to price $150 million 20-year exchangeables talked to yield 3%-3.5%, up 25%-30%
|
1/3/2012 | CV | Market Commentary: Chesapeake Energy adds 0.75 point dollar neutral; Micron, SanDisk active; Amarin to price
|
7/27/2011 | SP | New Issue: RBC prices $870,000 27.4% reverse convertibles linked to Amarin
|
4/26/2011 | SP | Market Commentary: RBC's $650,000 31.8% reverse convertibles tied to Amarin pay high coupon, reflect volatility
|
4/25/2011 | SP | New Issue: RBC prices $650,000 31.8% reverse convertibles linked to Amarin
|
3/29/2011 | CVHYPF | Amarin files automatic shelf for common stock, preference stock, debt
|
11/10/2010 | CVHYPF | Amarin files $150 million shelf for stock, preference shares, debt
|
10/13/2009 | PP | New Issue: Amarin orchestrates $70 million placement of American Depositary Shares
|
10/13/2009 | PP | Market Commentary: Amarin to raise $70 million; Corcept seeks $18 million; Midlands Minerals eyes units sale
|
8/3/2009 | PP | New Issue: Amarin plans $3 million placement of 8% convertible bridge loan notes
|
8/3/2009 | PP | Market Commentary: La Cortez Energy raises $6.33 million; International Ferro wraps sale; Amarin gets bridge loan
|
7/8/2009 | PP | New Issue: Amarin orchestrates $55 million placement of American Depositary Shares
|
7/8/2009 | PP | Market Commentary: Amarin to take in $55 million; Nile to raise $3.4 million; Cobra Oil secures equity financing
|
5/26/2009 | PP | New Issue: Amarin to place $2.6 million 8% convertible bridge loan notes, warrants
|
5/26/2009 | PP | Market Commentary: Vical increases direct offering; Amarin inks deal; Forest Gate to sell units; Jackgreen settles
|
5/14/2008 | PP | New Issue: Amarin plans $60 million private placements of stock, ADSs
|
5/14/2008 | PP | Market Commentary: Stockgroup cements new relationship; Broadpoint eyes opportunities; Amarin, Oxus raise for development
|
12/5/2007 | PP | New Issue: Amarin to sell $8.13 million of debentures, equity units in direct placement
|
6/4/2007 | PP | New Issue: Amarin seals $3.7 million direct placement of stock
|
6/4/2007 | PP | Market Commentary: Palm grabs $325 million for cash distribution plan; EV Energy raises $117 million
|
6/1/2007 | PP | New Issue: Amarin obtains $15 million equity line
|
11/9/2006 | BT | Amarin's cash balance grows to $22.5 million; will fund current and upcoming trials
|
10/19/2006 | PP | Market Commentary: Vical wraps up another direct stock offering; Siga secures $9.08 million from PIPE
|
10/19/2006 | BTPP | New Issue: Amarin set to wrap $18.7 million direct placement of shares
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
8/3/2006 | BT | Amarin 2Q net loss widens slightly to $6.8 million, operating loss to $7.9 million
|
7/27/2006 | BT | Amarin completes patient enrollment in Huntington's disease trial
|
7/12/2006 | BTCVHY | Amarin files $100 million shelf
|
7/11/2006 | BT | Amarin retains Nasdaq listing, adds AIM and IEX
|
6/29/2006 | BT | Amarin reaches target enrollment in phase 3 trial of Miraxion for Huntington's disease
|
6/9/2006 | BT | Nasdaq-listed Amarin seeks additional listing on AIM and IEX markets
|
5/18/2006 | BT | Amarin to develop oral apomorphine formula within six months
|
5/17/2006 | BT | Amarin acquires rights to oral apomorphine formulation
|
5/11/2006 | BT | Amarin reports net loss of $6.4 million, remains focused on bringing Miraxion for Huntington's to market
|
4/7/2006 | BT | Amarin: Preclinical studies show Miraxion improves learning, memory associated with neurodegenerative diseases
|
3/30/2006 | BTPP | New Issue: Amarin plans $4.18 million direct placement of stock
|
3/7/2006 | BT | Amarin reports Miraxion improves stress hormone transport through blood brain barrier
|
1/23/2006 | BTPP | New Issue: Amarin gets agreement for $2 million sale of stock
|
1/10/2006 | BT | Amarin's Miraxion improves Parkinson's disease symptoms, studies say
|
1/3/2006 | BT | Amarin licenses multiple sclerosis fatigue drug to Multicell
|
12/20/2005 | PP | Market Commentary: Maxwell Technologies raises $25 million from convertibles; Horizon Offshore wraps stock sale
|
12/19/2005 | PP | Market Commentary: Amarin to settle $26.36 million PIPE; Inovio secures agreements for $15.8 million stock deal
|
12/19/2005 | BTPP | New Issue: Amarin gets agreements for $26.36 million offering of American Depositary Shares
|
12/15/2005 | BT | Amarin begins European phase 3 trial of Miraxion in Huntington's disease
|
11/16/2005 | BT | Amarin says research shows Miraxion fights brain declines from Alzheimer's, Parkinson's, Huntington's diseases
|
5/20/2005 | PP | Market Commentary: Amarin arranges $17.81 million direct offering; volume ends week on a strong note
|
5/20/2005 | PP | New Issue: Amarin raises $17.81 million in direct placement of ADS
|
10/7/2004 | PP | Amarin's $12.75 million stock sale leads American private placements
|